Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.

[No authors listed]

Ann Neurol. 1997 Nov;42(5):747-55. Erratum in: Ann Neurol 1998 Aug;44(2):292.

PMID:
9392574
2.
3.
4.
5.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
7.

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):15-20. doi: 10.1097/WNF.0b013e318241520b.

PMID:
22222634
8.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
9.

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.

Rinne UK, Larsen JP, Siden A, Worm-Petersen J.

Neurology. 1998 Nov;51(5):1309-14.

PMID:
9818851
10.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K; ComQol Study Group.

Acta Neurol Scand. 2005 Jan;111(1):21-8.

PMID:
15595934
11.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

13.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
14.

[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].

Kulisevsky J.

Neurologia. 1999 Aug-Sep;14(7):349-58. Review. Spanish.

PMID:
10570622
15.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
17.

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

Brooks DJ, Leinonen M, Kuoppamäki M, Nissinen H.

J Neural Transm (Vienna). 2008 Jun;115(6):843-9. doi: 10.1007/s00702-008-0025-8. Epub 2008 Feb 8.

PMID:
18259682
19.

A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease.

Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P; BIA-3202-202 Study Investigators.

CNS Neurosci Ther. 2010 Dec;16(6):337-47. doi: 10.1111/j.1755-5949.2010.00145.x.

PMID:
20653695
20.
Items per page

Supplemental Content

Write to the Help Desk